258 related articles for article (PubMed ID: 30523261)
1. An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma.
Sun H; Yang W; Tian Y; Zeng X; Zhou J; Mok MTS; Tang W; Feng Y; Xu L; Chan AWH; Tong JH; Cheung YS; Lai PBS; Wang HKS; Tsang SW; Chow KL; Hu M; Liu R; Huang L; Yang B; Yang P; To KF; Sung JJY; Wong GLH; Wong VWS; Cheng ASL
Nat Commun; 2018 Dec; 9(1):5214. PubMed ID: 30523261
[TBL] [Abstract][Full Text] [Related]
2. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
[TBL] [Abstract][Full Text] [Related]
3. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients.
Feng H; Yu Z; Tian Y; Lee YY; Li MS; Go MY; Cheung YS; Lai PB; Chan AM; To KF; Chan HL; Sung JJ; Cheng AS
J Hepatol; 2015 May; 62(5):1100-11. PubMed ID: 25500144
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis.
Yu Z; Gao YQ; Feng H; Lee YY; Li MS; Tian Y; Go MY; Yu DY; Cheung YS; Lai PB; Yu J; Wong VW; Sung JJ; Chan HL; Cheng AS
Gut; 2014 Nov; 63(11):1793-804. PubMed ID: 24440987
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives β-catenin/T cell factor-dependent hepatocarcinogenesis.
Feng H; Cheng AS; Tsang DP; Li MS; Go MY; Cheung YS; Zhao GJ; Ng SS; Lin MC; Yu J; Lai PB; To KF; Sung JJ
J Clin Invest; 2011 Aug; 121(8):3159-75. PubMed ID: 21747169
[TBL] [Abstract][Full Text] [Related]
6. Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation.
Yu Z; Feng H; Zhuo Y; Li M; Zhu X; Huang L; Zhang X; Zhou Z; Zheng C; Jiang Y; Le F; Yu DY; Cheng AS; Sun X; Gao Y
Cell Oncol (Dordr); 2020 Dec; 43(6):1129-1145. PubMed ID: 32623699
[TBL] [Abstract][Full Text] [Related]
7. Bufalin suppresses hepatocarcinogenesis by targeting β-catenin/TCF signaling via cell cycle-related kinase.
Yu Z; Feng H; Sun X; Zhuo Y; Li M; Zhou Z; Huang L; Jiang Y; Zhu X; Zhang X; Le F; Zheng C; Cheng AS; Gao Y
Sci Rep; 2018 Mar; 8(1):3891. PubMed ID: 29497076
[TBL] [Abstract][Full Text] [Related]
8. Persistent mTORC1 activation via Depdc5 deletion results in spontaneous hepatocellular carcinoma but does not exacerbate carcinogen- and high-fat diet-induced hepatic carcinogenesis in mice.
Xu L; Yang C; Wang J; Li Z; Huang R; Ma H; Ma J; Wang Q; Xiong X
Biochem Biophys Res Commun; 2021 Nov; 578():142-149. PubMed ID: 34562654
[TBL] [Abstract][Full Text] [Related]
9. CCRK is a novel signalling hub exploitable in cancer immunotherapy.
Mok MT; Zhou J; Tang W; Zeng X; Oliver AW; Ward SE; Cheng AS
Pharmacol Ther; 2018 Jun; 186():138-151. PubMed ID: 29360538
[TBL] [Abstract][Full Text] [Related]
10. Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis.
Zeng X; Zhou J; Xiong Z; Sun H; Yang W; Mok MTS; Wang J; Li J; Liu M; Tang W; Feng Y; Wang HK; Tsang SW; Chow KL; Yeung PC; Wong J; Lai PB; Chan AW; To KF; Chan SL; Xia Q; Xue J; Chen X; Yu J; Peng S; Sung JJ; Kuang M; Cheng AS
Cell Mol Immunol; 2021 Apr; 18(4):1005-1015. PubMed ID: 32879468
[TBL] [Abstract][Full Text] [Related]
11. mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.
Zhang S; Zhou YF; Cao J; Burley SK; Wang HY; Zheng XFS
Cancer Res; 2021 Nov; 81(22):5652-5665. PubMed ID: 34429326
[TBL] [Abstract][Full Text] [Related]
12. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
13. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
14. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
15. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition.
Umemura A; Park EJ; Taniguchi K; Lee JH; Shalapour S; Valasek MA; Aghajan M; Nakagawa H; Seki E; Hall MN; Karin M
Cell Metab; 2014 Jul; 20(1):133-44. PubMed ID: 24910242
[TBL] [Abstract][Full Text] [Related]
16. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
[TBL] [Abstract][Full Text] [Related]
17. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway.
Qiu J; Zhang S; Wang P; Wang H; Sha B; Peng H; Ju Z; Rao J; Lu L
Cancer Med; 2020 Nov; 9(21):8159-8172. PubMed ID: 32977361
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma.
Ng SS; Cheung YT; An XM; Chen YC; Li M; Li GH; Cheung W; Sze J; Lai L; Peng Y; Xia HH; Wong BC; Leung SY; Xie D; He ML; Kung HF; Lin MC
J Natl Cancer Inst; 2007 Jun; 99(12):936-48. PubMed ID: 17565152
[TBL] [Abstract][Full Text] [Related]
19. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.
Yang J; Cai X; Lu W; Hu C; Xu X; Yu Q; Cao P
Cancer Lett; 2013 Jan; 328(2):243-51. PubMed ID: 23032719
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
